Vertex Shares Slide 3.07% as Major Indexes Rise

Vertex Pharmaceuticals shares fell 3.07% to $506.74 in the latest session, while the S&P 500 rose 0.2%. The Dow and Nasdaq each gained 0.04%.

The stock lost 6.1% over the previous month, compared with a 1.75% decline for the Medical sector and a 0.35% drop for the S&P 500.

Zacks consensus estimates call for quarterly earnings of $4.86 per share, up 1.25% from the year-earlier quarter, and revenue of $3.4 billion, a 10.43% increase. For the full year, the consensus forecast is $18.85 per share in earnings and $13.21 billion in revenue.

The consensus earnings estimate has fallen 0.95% over the past month, according to Zacks. Vertex trades at a forward price-to-earnings ratio of 27.73, above the industry average of 22.46.